pharmaphorum

CHMP backs first drug for lung disease bronchiectasis

Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...
Pharmabiz

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...
The American Journal of Managed Care

Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis

Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group.
Pharmabiz

Insmed to present multiple analyses from phase 3 ASPEN study at the American College of Chest Physicians Annual Meeting 2025

Bridgewater, New Jersey Saturday, October 18, 2025, 18:00 Hrs [IST] ...

Should Insmed’s (INSM) EMA Nod for BRINSUPRI Prompt a Fresh Look at Its Growth Prospects?

On October 17, 2025, Insmed announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of BRINSUPRI for non-cystic ...
Medscape

EMA OKs First Therapy for Non-Cystic Fibrosis Bronchiectasis

The EMA recommendation comes after a phase 3 randomized, double-blind, placebo-controlled clinical trial which involved 1721 patients aged 12 and older. Patients were treated with either 10 mg or 25 ...

Sanofi and Insmed among winners of EU drug recommendations this week

Sanofi (SNY) stock and Insmed (INSM) stock are in focus as new treatments from the companies win backing from an expert panel ...

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...